



December 1, 2013  
Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 5778-revised.docx).

**Title:** Sequencing of Treatment in Metastatic Colorectal Cancer: where to fit the target?

**Author:** Sally Temraz, Deborah Mukherji, Ali Shamseddine

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 5778

The manuscript has been improved according to the suggestions of reviewers:

1 Format of the paper has been updated according to Format for Topic Highlight which included formatting and adding the headings on pages 1 and 2 as well as modifying the abstract to include more than 200 words.

2 Revision has been made according to the suggestions of the reviewer

(1) Sentence 1 in introduction has been rephrased as such: Even though appropriate screening and preventive strategies are in place in many countries, a significant number of patients are still diagnosed at late stages of the disease.

(2) Sentence 4 in introduction has been modified to indicate that metastatic disease refers to distant metastasis

(3) A sentence has been added in the second paragraph to indicate that the presented data is valid to both rectal and colon cancers

(4) It has been indicated at the first instance where R0 resection appears in the text that it involves resected hepatic metastasis.

(5) FU alone has been replaced with 5-FU in all the text

(6) AIO (Arbeitsgemeinschaft Internistische Onkologie) has been explained on page 7 instead of page 11

(7) (KRAS exons 2, 3 or NRAS exons 2, 3, 4) has been changed to (KRAS exons 3, 4 or NRAS exons 2, 3, 4) on page 10 and mutated KRAS (exon 2 or 3) has been changed to KRAS (exon 3 or 4) on page 13.

(8) an indication that the microsatellite stable BRAF mutated tumors are associated with a poor prognosis has been added based on the study by Bettington et al

(9) "shall" has been changed to "can" the last sentence of the section on First Line Folfoxiri, subsection bevacizumab.

(10) on page 18 ECOG has been inserted

(11) conflicts of interest are as follows however none are related to writing this paper

Conflicts of interest: Sally Temraz declares receiving travel support from Roche. Deborah Mukherji declares receiving travel support from Roche and Merck. Ali Shamseddine declares receiving research grants from Roche, Sanofi and Novartis and honoraria from Roche, Sanofi and Amgen and is on the advisory board of Roche, Sanofi, Pharmamed and Amgen.

3 English editing: the paper has been reviewed by Deborah Mukherji who is a native English speaker.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Sally Temraz, MD

Department of medicine, division of hematology-oncology

American University of Beirut Medical Center

Riad El Solh 110 72020

Beirut, Lebanon

Telephone: +961-1-374374 ext: 5390

Fax: +961-1-370814

E-mail: [st29@aub.edu.lb](mailto:st29@aub.edu.lb)